Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Quek L, David MD, Kennedy A, Metzner M, Amatangelo M, Shih A, Stoilova B, Quivoron C, Heiblig M, Willekens C, Saada V, Alsafadi S, Vijayabaskar MS, Peniket A, Bernard OA, Agresta S, Yen K, MacBeth K, Stein E, Vassiliou GS, Levine R, De Botton S, Thakurta A, Penard-Lacronique V, Vyas P. Quek L, et al. Among authors: heiblig m. Nat Med. 2018 Aug;24(8):1167-1177. doi: 10.1038/s41591-018-0115-6. Epub 2018 Jul 16. Nat Med. 2018. PMID: 30013198 Free PMC article.
Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: A multicenter retrospective study of 59 cases.
Zakine È, Papageorgiou L, Bourguiba R, Mekinian A, Terrier B, Kosmider O, Hirsch P, Jachiet M, Audia S, Ardois S, Adélaïde L, Bigot A, Duriez P, Emile JF, Lazaro E, Fayard D, Galland J, Hié M, Humbert S, Jean A, Kostine M, Lacombe V, Le Guenno G, Lobbes H, Magy-Bertrand N, Marianetti-Guingel P, Mathian A, Outh R, Saillard C, Samson M, Vial G, Bouaziz JD, Moguelet P, Chasset F; National French VEXAS Study Group (NFVS). Zakine È, et al. J Am Acad Dermatol. 2023 Apr;88(4):917-920. doi: 10.1016/j.jaad.2022.10.052. Epub 2022 Nov 5. J Am Acad Dermatol. 2023. PMID: 36343774 No abstract available.
Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters.
Bruch PM, Dietrich S, Finel H, Boumendil A, Greinix H, Heinicke T, Bethge W, Beelen D, Schmid C, Martin H, Castagna L, Scheid C, Schäfer-Eckart K, Bittenbring J, Finke J, Sengeloev H, Heiblig M, Cornelissen J, Chevallier P, Mohty M, Robinson S, Montoto S, Dreger P. Bruch PM, et al. Among authors: heiblig m. Leukemia. 2023 Feb;37(2):465-472. doi: 10.1038/s41375-022-01782-z. Epub 2022 Dec 22. Leukemia. 2023. PMID: 36550212
VEXAS: where do we stand 2 years later?
Sujobert P, Heiblig M, Jamilloux Y. Sujobert P, et al. Among authors: heiblig m. Curr Opin Hematol. 2023 Mar 1;30(2):64-69. doi: 10.1097/MOH.0000000000000750. Epub 2022 Dec 30. Curr Opin Hematol. 2023. PMID: 36728604 Review.
Quantitative Assessment of Vacuolization of Myeloid Precursors in VEXAS Syndrome.
Rabut A, Jasserand L, Richard C, Dumas C, Mestrallet F, Bourbon E, Gerfaud Valentin M, Heiblig M, Eveillard M, Jamilloux Y, Sujobert P. Rabut A, et al. Among authors: heiblig m. Hemasphere. 2023 Jan 25;7(2):e828. doi: 10.1097/HS9.0000000000000828. eCollection 2023 Feb. Hemasphere. 2023. PMID: 36751512 Free PMC article. No abstract available.
Recurrent Mutations of the Active Adenylation Domain of UBA1 in Atypical Form of VEXAS Syndrome.
Faurel A, Heiblig M, Kosmider O, Cornillon J, Boudou L, Guyotat D, Martignoles JA, Jamilloux Y, Noyel P, Daguenet E, Faure AC, Sujobert P, Flandrin-Gresta P. Faurel A, et al. Among authors: heiblig m. Hemasphere. 2023 Mar 24;7(4):e868. doi: 10.1097/HS9.0000000000000868. eCollection 2023 Apr. Hemasphere. 2023. PMID: 36999004 Free PMC article. No abstract available.
VEXAS: is it time to reshape the nosology of clonal hematopoiesis?
Sujobert P, Largeaud L, Jamilloux Y, Heiblig M, Kosmider O. Sujobert P, et al. Among authors: heiblig m. Expert Rev Hematol. 2023 Jul-Dec;16(7):495-499. doi: 10.1080/17474086.2023.2209715. Epub 2023 May 4. Expert Rev Hematol. 2023. PMID: 37119011
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression.
Stein EM, de Botton S, Cluzeau T, Pigneux A, Liesveld JL, Cook RJ, Rousselot P, Rizzieri DA, Braun T, Roboz GJ, Lebon D, Heiblig M, Baker K, Volkert A, Paul S, Rajagopal N, Roth DA, Kelly M, Peterlin P. Stein EM, et al. Among authors: heiblig m. Leuk Lymphoma. 2023 Dec;64(12):1992-2001. doi: 10.1080/10428194.2023.2243356. Epub 2023 Aug 12. Leuk Lymphoma. 2023. PMID: 37571998
80 results